NCT06369155

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Joyce Liu, MD · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Detailed description

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. Azenosertib has been tested as a treatment for other diseases and has shown to stop cancer cell growth. The U.S. Food and Drug Administration (FDA) has not approved Azenosertib as a treatment for recurrent uterine serous carcinoma. This research study involves screening for eligibility, study treatment visits, X-rays, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, Positron Emission Tomography CT (PET-CT) scans, Meta-iodobenzylguanidine (MIBG) scans, Fluorodeoxyglucose Positron Emission Tomography), (FDG-PET) scans, Electrocardiograms (EKGs), tumor biopsies, and blood tests. It is expected that about 25 people will take part in this research study. Zentalis Pharmaceuticals is supporting this research study by providing the study drug Azenosertib.

Conditions

• Uterine Serous Carcinoma
• Uterine Carcinoma
• Uterine Cancer

Interventions

Type	Name	Description
DRUG	Azenosertib	Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.

Timeline

• Start date: 2025-03-05
• Primary completion: 2027-01-31
• Completion: 2028-01-31
• First posted: 2024-04-16
• Last updated: 2026-03-02

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study